Aprea Therapeutics (NASDAQ:APRE – Get Free Report) issued its earnings results on Wednesday. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.02), FiscalAI reports.
Aprea Therapeutics Stock Performance
Shares of APRE traded down $0.02 during mid-day trading on Thursday, hitting $0.49. 12,968 shares of the company were exchanged, compared to its average volume of 824,842. The stock has a market cap of $6.17 million, a price-to-earnings ratio of -0.45 and a beta of 1.74. Aprea Therapeutics has a 1-year low of $0.41 and a 1-year high of $1.49. The company has a 50 day moving average of $0.68 and a 200-day moving average of $0.75.
Analyst Ratings Changes
Several analysts recently commented on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aprea Therapeutics in a report on Thursday, October 15th. LADENBURG THALM/SH SH began coverage on Aprea Therapeutics in a report on Wednesday, October 14th. They issued a “buy” rating and a $2.00 price target for the company. Finally, Wedbush lowered their price objective on Aprea Therapeutics to $3.00 and set an “outperform” rating on the stock in a research report on Thursday, August 13th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $2.80.
Read Our Latest Report on APRE
Aprea Therapeutics Company Profile
Aprea Therapeutics, Inc (NASDAQ: APRE) is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer. Its research is centered on small-molecule treatments intended to address molecular abnormalities that contribute to tumor growth and resistance to treatment.
The company’s lead historical program was eprenetapopt, also known as APR-246, an investigational therapy designed to reactivate mutant p53, a tumor-suppressor protein frequently altered in cancer.
Further Reading
- Five stocks we like better than Aprea Therapeutics
- Matador Resources Insider Buying and the Case for a Dividend Stock Rebound
- Datadog’s Post-Earnings Sell-Off: A Buying Opportunity in Plain Sight?
- How Much of Tesla’s Robotaxi Future Is Already Priced In?
- 3 AI Infrastructure Plays Beyond Chipmakers
Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
